In-Person Access Only | 4.50 CME Credits
Please read: All programs remain free. Registrations will require a credit card as a cancellation hold. A fee of $99 will only be incurred in the event of a no-show or cancellation within 5 days without written confirmation to the Total Health Program Team. Industry representatives—defined as any individual who is employed by, contracted with, owns, or represents a drug, device, diagnostic, or other healthcare-related commercial entity, regardless of clinical credentials or licensure—are not permitted to attend Total Health events as general attendees. Members of industry must contact exhibits@totalhealthoncology.com
The First Annual DEBATING BREAST CANCER Symposium will take place January 22–23, 2027, in San Francisco, California. This first-of-its-kind educational forum brings together internationally recognized breast cancer experts for a series of engaging, evidence-based debates addressing the most controversial and practice-changing questions in breast oncology. Covering early-stage disease, metastatic breast cancer, and emerging future directions, faculty will present opposing viewpoints on evolving standards of care, novel therapeutics, biomarker-driven treatment strategies, clinical trial design, and the integration of cutting-edge technologies such as ctDNA and artificial intelligence. Designed to challenge conventional thinking and encourage thoughtful discussion, the symposium provides attendees with balanced perspectives, practical clinical insights, and actionable strategies to navigate the rapidly evolving breast cancer treatment landscape.
Conference Agenda
Friday, January 22, 2027
Program Chairs:
Chadi Nabhan, MD, MBA, FACP
Sarah Sammons, MD
3:00 - 4:00 PM
Arrival, Networking, and Registration
4:00 - 5:30 PM
Breakout Focus Groups
5:30 - 6:30 PM
Networking Reception
7:00 - 9:00 PM
Faculty Dinner
Saturday, January 23, 2027
7:30 AM
Coffee and Networking
8:00 AM
Welcome and Opening Remarks
Early Stage
8:15 AM
Debate 1: Should Giredestrant be part of adjuvant therapy for most patients with ER+ breast cancer?
Yes:
William Gradishar, MD | Northwestern Medicine
No:
Mark Pegram, MD | Stanford Medicine
8:45 AM
Debate 2: Is MRD ready for prime time in Early Breast Cancer?
Yes:
Sigrun Hallmeyer, MD | Advocate Health Care
No:
Matthew Kurian, MD | St. Elizabeth Healthcare
9:15 AM
Debate 3: Should T-DXd be given neo-adjuvantly or adjuvantly in early-stage HER2+ breast cancer?
Neo-adjuvantly (Destiny-Breast 11):
Kit Yu Lu, MD | University of Pittsburgh Medical Center
Adjuvantly (Destiny-Breast 5):
Yara Abdou, MD, MSCR, FASCO | UNC School of Medicine
9:45 AM
Snack and Coffee Break
10:15 AM
Non-CME Breakfast
11:00 AM
Networking Break
Advanced Stage
11:30 AM
Debate 4: Should TOPO1 ADCs be used in sequence?
No, chemo should be used immediately after ADCs:
Kelly McCann, MD, PhD | UC San Diego Moores Cancer Center
Yes, using ADCs in sequence is reasonable:
Alexis Ann LeVee, MD | UCLA Health
12:00 PM
Debate 5: First-line treatment for PD-L1- metastatic TNBC: should all patients receive Trop2 ADCs?
Yes, Trop2 ADCs should be always favored:
Gregory Vidal, MD, PhD | West Cancer Center
No, chemotherapy still has a role:
Olwen Hahn, MD | University of Chicago
12:30 PM
Debate 6: Should 1L T-DXd + pertuzumab be used until progression to treat HER2+ metastatic breast cancer?
Yes: if T-DXd/P is chosen, it should be given to progression:
Nisha Unni, MD | UT Southwestern Medical Center
No: an induction/maintenance strategy is still reasonable:
Mei Wei, MD | Huntsman Cancer Institute
1:00 PM
Lunch and Exhibits
1:30 PM
Non-CME Lunch
2:15 PM
Networking, Housekeeping Notes, and Survey
Future Directions
2:45 PM
Debate 7: Should liquid biopsy be used for serial monitoring of ESR1 mutation emergence in breast cancer?
YES: for all patients:
Amy Comander, MD | Mass General Cancer Center
NO: use selectively:
Oana Danciu, MD | University of Illinois
3:15 PM
Debate 8: Adjuvant CDK4/6 inhibitors in Breast Cancer
Abemaciclib:
Maryam Lustberg, MD, MPH | Yale School of Medicine
Ribociclib:
Sarah Sammons, MD | Sarah Sammons, MD
3:45 PM
Concluding Remarks
4:00 PM
Sponsored Focus Group Opportunities
5:00 PM
Adjourn
Agenda Subject To Change. All times are PST.
-
Identify controversial topics in managing patients across various malignancies discussed at these meetings.
Evaluate the role of emerging therapies in various solid cancers and hematologic malignancies, including new medications, targeted therapies, and immunotherapies.
Apply evidence-based strategies to improve patient outcomes in community oncology settings by integrating new treatment approaches.
Help the community oncology understand areas of debate and uncertainties in various cancers, and the evidence used to resolve these.
Discuss multidisciplinary care approaches that enhance collaboration between oncologists, pharmacists, nurses, and advanced practitioners in treating solid cancers and hematologic malignancies.
-
-
Complimentary registration for healthcare professionals
Evidence-based debates featuring internationally recognized breast cancer experts
Balanced perspectives on today's most controversial clinical questions
Practical strategies to help translate emerging evidence into clinical practice
Interactive discussion and networking with leading clinicians and peers
Access to the latest research, therapeutic advances, and industry innovations